Tocilizumab has been proposed as a means of opposing hyperinflammatory responses in intensive care patients with COVID-19. Here, we briefly discuss the potentially multiple, synergistic mechanisms whereby tocilizumab might exert therapeutic activity, mostly focusing on the production of tryptophan-derived catabolites that would result from blockade of IL-6 signaling, as contextualized to the cytokine storm occurring in COVID-19 patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319082 | PMC |
| http://dx.doi.org/10.3389/fphar.2020.00959 | DOI Listing |
Publication Analysis
Top Keywords
potential benefits
4
benefits tryptophan
4
tryptophan metabolism
4
metabolism efficacy
4
efficacy tocilizumab
4
tocilizumab covid-19
4
covid-19 tocilizumab
4
tocilizumab proposed
4
proposed opposing
4
opposing hyperinflammatory
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!